Dr. Omar Mamlouk, MD

Dr. Mamlouk practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Mamlouk's NPI, 1629489703, was assigned on May 12, 2014. Dr. Mamlouk graduated from Jordan University of Science and Technology FOM in 2009. Dr. Mamlouk holds Texas license S1174.

Dr. Mamlouk's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Mamlouk's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mamlouk practices. Vendor and product names are available with a free account.

Nephrology is Dr. Mamlouk's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Mamlouk is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Mamlouk's licenses on file in 10 states: Texas, Florida, Georgia, Washington, Arizona, Louisiana, Mississippi, Tennessee, Alabama and Oklahoma.

Dmand AI lists acute kidney failure, chronic kidney disease, fluid and electrolyte imbalances, hypercalcemia and kidney cysts among the conditions Dr. Mamlouk treats.

CMS data shows 969 Medicare services from Dr. Mamlouk across 9 procedure codes in 2024, for 312 Medicare patients. Medicare paid $98,200 for them.

CMS counts 312 Medicare patients who saw Dr. Mamlouk in 2024. The largest group is 65 to 74, with 149 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 7% are also on Medicaid. Their average risk score is 4.36, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mamlouk's median patient age at 69, with 50% women.

In 2024, Dr. Mamlouk wrote 41 Medicare Part D claims for 19 patients. 73% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $91 in total drug cost. In 2018, CMS named 13 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Mamlouk for performance year 2024, reported as part of a group. Dr. Mamlouk accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mamlouk as offering telehealth.

Dmand AI links 20 papers to Dr. Mamlouk, published from 2012 to 2025. 2020 was the busiest year, with 4. The most frequent topics are Acute Kidney Injury, Immune Checkpoint Inhibitors and Kidney. Dr. Mamlouk has published most often in Cancers (Basel). Dr. Mamlouk's most frequent co-authors are Ala Abudayyeh, MD, Maen Abdelrahim, MD and Jamie S. Lin, MD.

CMS Open Payments shows 5 general payments to Dr. Mamlouk from 4 drug and device companies from 2019 to 2022. Food and beverage make up the largest share, 100% of the total. Travere Therapeutics, Inc. paid the most, $73.

Dr. Mamlouk graduated from Jordan University of Science and Technology FOM in 2009.

Dr. Mamlouk is in network with 4 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 3. Check the plan with the practice before a visit.